

# ACRP-CP Trainingsmaterialien: ACRP Certified Professional Exam & ACRP-CP Lernmittel & ACRP ACRP-CP Quiz



Übrigens, Sie können die vollständige Version der ZertSoft ACRP-CP Prüfungsfragen aus dem Cloud-Speicher herunterladen:  
<https://drive.google.com/open?id=1ngZrtwqUCj9ZFEAk3De1VZBv1ZY1I9>

Tun Sie, was Sie gesagt haben, was Beginn des Erfolgs ist. Weil Sie die schwierige IT-Zertifizierungsprüfung ablegen wollen, sollen Sie sich bemühen, um das Zertifikat zu bekommen. Die Fragenkataloge zur ACRP ACRP-CP Prüfung von ZertSoft sind sehr gut. Mit Ihr können Sie Ihren Erfolg ganz leicht erzielen. Sie sind ganz zuverlässig. Ich glaube, Sie werden die Prüfung 100% bestehen.

Schulungsunterlagen zur ACRP ACRP-CP Zertifizierungsprüfung von ZertSoft sind effizient, die von manchen Experten und einigen bestandenen Kandidaten bewiesen sind. Sie sind fast gleich wie die echten ACRP-CP Prüfungsfragen. Sie können Ihnen dabei helfen, die ACRP-CP Zertifizierungsprüfung zu bestehen. Wir werden Ihnen alle Ihren bezahlten Summe zurückgeben, entweder Sie die ACRP-CP Prüfung nicht bestehen, oder die Testaufgaben von ACRP ACRP-CP irgend ein Qualitätsproblem haben. Vertrauen Sie bitte auf ZertSoft, denn wir werden Ihnen stets begleiten.

>> ACRP-CP Fragenkatalog <<

## ACRP-CP Fragen Beantworten & ACRP-CP Probesfragen

Das IT-Expertenteam hat nach ihren Kenntnissen und Erfahrungen die Qualität der Fragenpool immer noch verbessert, um die Bedürfnisse der Kandidaten abzudecken und den Kandidaten zu helfen, die ACRP ACRP-CP Zertifizierungsprüfung zu bestehen. Sie können im ZertSoft die neuesten und schnellsten und richtigsten bekommen. Die Produkte von ZertSoft sind sehr umfangreich und kann den Kandidaten viel Bequemlichkeiten bieten. Die Erfolgsquote beträgt 100%. Sie können ganz unbesorgt die ACRP ACRP-CP Prüfung ablegen und das Zertifikat bekommen.

## ACRP Certified Professional Exam ACRP-CP Prüfungsfragen mit Lösungen (Q69-Q74):

### 69. Frage

The IRB/IEC has decided to not approve a clinical trial. Who must they notify in writing?

- A. CRC
- **B. PI**
- C. Regulatory Agency
- D. Sponsor

**Antwort: B**

Begründung:

When the IRB/IEC decides not to approve a clinical trial, they must notify the Principal Investigator (PI) in writing. This communication ensures that the PI is formally informed of the decision and can take appropriate actions, such as revising the protocol or addressing the reasons for disapproval.

According to GCP guidelines, the IRB/IEC must communicate any decision regarding the approval status of a study directly to the PI, as the PI is responsible for the conduct of the trial.

"The IRB/IEC should promptly notify the investigator in writing of its decision to approve or disapprove the proposed research activity." Objectives:

- \* Maintain clear communication between the IRB/IEC and the investigator.
- \* Ensure timely notification of decisions affecting the study.

### 70. Frage

A potential subject is interested in a new clinical trial and would like to learn more about the risks and benefits of participation. Where can they find this information?

- A. IB
- B. Package insert
- **C. ICF**
- D. Protocol

**Antwort: C**

Begründung:

The Informed Consent Form (ICF) contains comprehensive information about the potential risks and benefits of participation in a clinical trial. It is a legally required document that ensures that subjects make an informed decision before enrollment.

The answer is consistent with GCP guidelines which mandate that the ICF clearly outlines the risks and benefits of participation to protect participant rights.

"The ICF should include a clear explanation of potential risks and benefits to ensure informed decision-making by the participant."

Objectives:

- \* Ensure informed decision-making by potential subjects.
- \* Provide transparent risk-benefit information.

### 71. Frage

Preliminary evidence suggests a low-dose anti-cancer drug given for a short period of time may reduce the risk of developing cancer in patients who are at increased risk for developing cancer. The drug has potentially serious side effects. What is the MOST important question to consider before designing a clinical trial to test this hypothesis?

- A. How willing are current patients to participate in a trial with potentially serious side effects?
- **B. How does the risk of developing cancer compare to the anticipated side effects from the drug?**
- C. How likely are patients at high risk of cancer going to develop cancer during the study?
- D. How effective is the drug at treating patients that have been previously diagnosed with cancer?

**Antwort: B**

Begründung:

Before initiating a clinical trial with a drug that has potentially serious side effects, it is essential to evaluate the risk-benefit ratio. The primary consideration is whether the potential benefits (reduced cancer risk) outweigh the risks (serious side effects). This assessment is fundamental to ethical clinical trial design.

The answer is verified as per GCP and ethical guidelines, which require a thorough assessment of risk versus benefit before

conducting human trials.

"An assessment of potential benefits versus risks is a fundamental principle in the ethical design of clinical trials, especially when potential adverse effects are severe." Objectives:

- \* Ensure ethical considerations in trial design.
- \* Assess the potential harm versus benefit to participants.

## 72. Frage

A printed, optical, or electronic document designed to record all of the protocol-required information and is transmitted to the sponsor is called a:

- A. Source document.
- B. Worksheet.
- **C. CRF.**
- D. PRO.

**Antwort: C**

Begründung:

A Case Report Form (CRF) is a tool used in clinical trials to collect data as specified by the protocol. It is a printed, optical, or electronic document designed to record all protocol-required information for each trial subject. CRFs are crucial for ensuring that the data collected during the trial is accurate, complete, and consistent with the protocol.

This answer follows GCP guidelines, which describe CRFs as essential documents for capturing and transmitting study data to the sponsor.

"A Case Report Form (CRF) is a printed, optical, or electronic document specifically designed to record all protocol-required information to be reported to the sponsor on each trial subject." Objectives:

- \* Understand the role of CRFs in clinical trials.
- \* Ensure accurate and complete data collection.

## 73. Frage

An audit was recently completed and identified non-compliance that could potentially affect the reliability of study results. Who should perform a root cause analysis and implement appropriate corrective and preventive actions?

- A. DSMB/IDMC
- B. IRB/IEC
- **C. PI**
- D. Sponsor

**Antwort: C**

Begründung:

The Principal Investigator (PI) is responsible for conducting a root cause analysis when non-compliance is identified at the site. The PI must identify the reasons for non-compliance and develop a Corrective and Preventive Action (CAPA) plan to address and prevent future occurrences.

This answer aligns with GCP principles that designate the PI as responsible for site-level compliance and corrective actions.

"The PI must take responsibility for investigating the cause of non-compliance and developing a CAPA plan to mitigate recurrence." Objectives:

- \* Maintaining compliance and data integrity
- \* Addressing non-compliance proactively

## 74. Frage

.....

Wir alle sind normale Menschen, Manchmal können wir nicht alles schnell im Kopf behalten. Im Laufe der Zeit haben wir vieles vergessen. So sollen wir manchmal dieses wiederholen. Wenn Sie die Prüfungsmaterialien zur ACRP ACRP-CP

Zertifizierungsprüfung von ZertSoft sehen, würden Sie finden, dass Sie genau was sind, was Sie wollen. Sie brauchen sich nicht so anstrengend um die ACRP-CP Zertifizierung vorzubereiten und fleißig zu wiederholen. Sie sollen ZertSoft glauben und werden eine glänzende Zukunft haben.

